HOTHHoth Therapeutics Inc
HOTH
Hoth Therapeutics Inc11,529
Mkt Cap
$14.19MVolume
230,909.0052W High
$2.1252W Low
$0.6554PE Ratio
-0.86HOTH Fundamentals
Price
$0.9146Prev Close
$0.9234Open
$0.9250D MA
$0.9951Beta
1.04Avg. Volume
533,189.84EPS (Annual)
-$1.28P/B
1.68Rev/Employee
$0.00$2.24
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model Hoth Therapeutics Reports Positive Female Preclinical...
PR Newswire·12d ago
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program PR Newswire...
PR Newswire·18d ago
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND...
PR Newswire·25d ago
Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases
Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy...
PR Newswire·1mo ago
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets PR Newswire NEW YORK, Feb. 5, 2026 NEW...
PR Newswire·1mo ago
Hoth Therapeutics Early Cancer Trial Succeeds With 100% Patient Response, Cuts Disease Severity By Half
Hoth Therapeutics reported interim trial results showing all patients improved by Week 6, with reduced disease severity, fewer side effects, and early lasting benefits in cancer patients on EGFR...
Benzinga·2mo ago
Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients
Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients Hoth Therapeutics Delivers 100% Clinical Response...
PR Newswire·2mo ago
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position Hoth Therapeutics Secures Major International Patent Milestone for...
PR Newswire·2mo ago
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation Hoth Therapeutics Reaches Key EU Regulatory Inflection Point...
PR Newswire·2mo ago
<
1
2
...
>